Ruilong Lu

Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Nuclear factor erythroid 2-related factor 2 as targets to treat chronic obstructive pulmonary disease: toward new perspectives.

Nuclear factor erythroid 2-related factor 2 as targets to treat chronic obstructive pulmonary disease: toward new perspectives.

Journal: Therapeutic advances in respiratory disease

Published: August 17, 2026

Effective-Component Compatibility of Bufei Yishen Formula III Improves Chronic Obstructive Pulmonary Disease by Inhibiting Inflammatory Responses Through Blocking PTX3 Activation.

Effective-Component Compatibility of Bufei Yishen Formula III Improves Chronic Obstructive Pulmonary Disease by Inhibiting Inflammatory Responses Through Blocking PTX3 Activation.

Journal: Journal of inflammation research

Published: April 01, 2026

Effective-Component Compatibility of Bufei Yishen Formula Alleviates Alveolar Epithelial Barrier Damage in COPD Through Inhibition of p38 MAPK Phosphorylation.

Effective-Component Compatibility of Bufei Yishen Formula Alleviates Alveolar Epithelial Barrier Damage in COPD Through Inhibition of p38 MAPK Phosphorylation.

Journal: International journal of chronic obstructive pulmonary disease

Published: January 12, 2026

Cigarette smoke combined with Klebsiella pneumoniae induce damage to the air‑blood barrier in chronic obstructive pulmonary disease rats via the MAPK/NF‑κB/IκBα pathway.

Cigarette smoke combined with Klebsiella pneumoniae induce damage to the air‑blood barrier in chronic obstructive pulmonary disease rats via the MAPK/NF‑κB/IκBα pathway.

Journal: Molecular medicine reports

Published: July 24, 2025

Electroacupuncture stimulation improves pulmonary fibrosis by modulating ferroptosis in rats: multiscale analysis of transcriptome and proteome.

Electroacupuncture stimulation improves pulmonary fibrosis by modulating ferroptosis in rats: multiscale analysis of transcriptome and proteome.

Journal: Chinese medicine

Published: March 17, 2025

Effective Component Compatibility of Bufei Yishen Formula III Alleviates Pulmonary Vascular Inflammation in COPD: Via VEGF165/P38 MAPK Pathway.

Effective Component Compatibility of Bufei Yishen Formula III Alleviates Pulmonary Vascular Inflammation in COPD: Via VEGF165/P38 MAPK Pathway.

Journal: Journal of inflammation research

Published: February 17, 2025

Integrating single-cell analysis and machine learning to identify COPD hub genes and explore the intervention mechanism of effective component compatibility of Bufei Yishen formula III.

Integrating single-cell analysis and machine learning to identify COPD hub genes and explore the intervention mechanism of effective component compatibility of Bufei Yishen formula III.

Journal: Journal of ethnopharmacology

Published: February 14, 2025

Mechanism of effective-component compatibility of Bufei Yishen formula Ⅲ in COPD and identification of hub genes.

Mechanism of effective-component compatibility of Bufei Yishen formula Ⅲ in COPD and identification of hub genes.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: January 26, 2025

Effective-Component Compatibility of Bufei Yishen Formula III Protects Lung Air-Blood Barrier by Regulating the Oxidative Stress: via the Nuclear Factor-E2-Related Factor 2 Pathway.

Effective-Component Compatibility of Bufei Yishen Formula III Protects Lung Air-Blood Barrier by Regulating the Oxidative Stress: via the Nuclear Factor-E2-Related Factor 2 Pathway.

Journal: International journal of chronic obstructive pulmonary disease

Published: December 18, 2024

Mechanism underlying the therapeutic effects of effective component compatibility of Bufei Yishen formula III combined with exercise rehabilitation on chronic obstructive pulmonary disease.

Mechanism underlying the therapeutic effects of effective component compatibility of Bufei Yishen formula III combined with exercise rehabilitation on chronic obstructive pulmonary disease.

Journal: Annals of medicine

Published: September 14, 2024

Bleomycin pollution and lung health: The therapeutic potential of peimine in bleomycin-induced pulmonary fibrosis by inhibiting glycolysis.

Bleomycin pollution and lung health: The therapeutic potential of peimine in bleomycin-induced pulmonary fibrosis by inhibiting glycolysis.

Journal: Ecotoxicology and environmental safety

Published: July 15, 2024

Effective-Component Compatibility of Bufei Yishen Formula III Suppresses Mitochondrial Oxidative Damage in COPD: Via Pkm2/Nrf2 Pathway.

Effective-Component Compatibility of Bufei Yishen Formula III Suppresses Mitochondrial Oxidative Damage in COPD: Via Pkm2/Nrf2 Pathway.

Journal: International journal of chronic obstructive pulmonary disease

Published: May 08, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026